Research develops a self micro emulsifying drug delivery system for haloperidol, enhancing drug release in schizophrenia treatment.
The objective of the present research work was to formulate Selfmicroemulsifying drug delivery system of Haloperidol for the treatment of Schizophrenia. By using 32 full factorial design optimization of Haloperidol SMEDDS was done. Spectrometric analysis of Haloperidol was done by using a UVVisible Spectrophotometer and Drug-Excipients compatibility study was conducted by Fourier Transform Infrared Spectroscopy. Oil, Surfactant, and Co-Surfactant were selected based on the results of a solubility study for the formulation of SMEDDS, while the ratio of Surfactant to CoSurfactant (S-mix) was determined through a pseudo ternary phase diagram study. 32 full factorial design was applied using Design Expert 13.5 software. Concentration of Oil (X1) and Ratio of S-mix (X2) were chosen as an independent variable, while Globule size (Y1), Emulsification time (Y2) and % Drug release (Y3) were selected as dependent variables. All nine microemulsions were evaluated for different parameters such as pH, Viscosity, Cloud point, % Drug content, % Transmittance, Globule size and Polydispersity index (PDI), Emulsification time and % Drug release. A checkpoint was prepared and evaluated for the validation of the model. Optimized SMEDDS was subjected to a stability study under accelerated conditions for one month. Percentage drug release of optimized batch is higher as compared with the marketed formulation. So, it concluded that SMEDDS formulation is best to improve the solubility of poorly water-soluble drug like Haloperidol. Hence, a clear and stable Liquid SMEDDS of Haloperidol was formulated successfully
No takes yet. Share an insight, caveat, or question.
Panchal et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: